Article | June 13, 2024

Including Diversity At The Onset

Source: Citeline
GettyImages-1386401112 patient diversity

Claire Riches, Citeline Vice President of Clinical Solutions, emphasizes the importance of beginning clinical trial diversity efforts with a fit-for-purpose clinical protocol, incorporating diversity and patient voices early in the process. In a recent webinar, Citeline experts discussed best practices for enhancing diversity in clinical trials, highlighting efforts by companies like GSK and Pfizer.

GSK embeds population-related scientific questions in study protocols and harmonizes data collection, while Pfizer commits to achieving trial participation at census or disease epidemiology levels. AbbVie and Bristol Myers Squibb are also advancing diversity initiatives, with AbbVie evolving protocols and Bristol Myers Squibb supporting diverse clinical investigators through the Robert A. Winn Diversity in Clinical Trials Award program.

Despite challenges in start-up financing, the field continues to progress, underscoring the critical role of inclusive designs and the patient voice in clinical trials. Access the full article to learn more about techniques and methods for incorporating diversity into clinical planning.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader